We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$489M
AUM Growth
+$31.8M
Cap. Flow
+$69.7M
Cap. Flow %
14.26%
Top 10 Hldgs %
49.33%
Holding
85
New
24
Increased
27
Reduced
16
Closed
16

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$12.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$9.19M
4
SLNO
Soleno Therapeutics
SLNO
+$8.1M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$7.71M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$17.3M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15M
3
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$9.72M
4
SRRK icon
Scholar Rock
SRRK
+$7.92M
5
COGT icon
Cogent Biosciences
COGT
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
2 Miscellaneous 2.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$34.7M 7.09%
545,872
+29,858
+6% +$1.79M
MRUS
2
DELISTED
Merus
MRUS
$34.1M 6.98%
811,021
+130,176
+19% +$5.68M
NUVL
3
DELISTED
Nuvalent
NUVL
$31.1M 6.37%
439,018
+39,004
+10% +$3.05M
AKRO
4
DELISTED
Akero Therapeutics
AKRO
$29.1M 5.96%
719,992
-19,571
-3% -$830K
INSM icon
5
Insmed
INSM
$25.9B
$24.5M 5.01%
321,366
-50,864
-14% -$3.89M
KALV
6
DELISTED
KalVista Pharmaceuticals
KALV
$19.6M 4.01%
1,698,984
+1,086,811
+178% +$11.1M
VCYT icon
7
Veracyte
VCYT
$3.48B
$18.8M 3.84%
633,832
+130,551
+26% +$4.98M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.38B
$17.9M 3.66%
337,605
+63,709
+23% +$3.53M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.74B
$16.1M 3.29%
1,309,224
+78,824
+6% +$1.11M
URGN icon
10
UroGen Pharma
URGN
$2.13B
$15.3M 3.12%
1,381,158
+260,685
+23% +$2.78M
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$12.1M 2.48%
411,312
-132,339
-24% -$4.12M
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$11.9M 2.43%
+166,417
New +$8.1M
ASND icon
13
Ascendis Pharma A/S
ASND
$16.3B
$11.8M 2.41%
75,751
+24,260
+47% +$3.47M
IRON icon
14
Disc Medicine
IRON
$3.07B
$11.7M 2.4%
236,471
+126,090
+114% +$7.01M
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.37B
$11.5M 2.35%
2,060,240
+881,940
+75% +$7.71M
ETNB
16
DELISTED
89bio
ETNB
$11M 2.25%
1,510,498
+1,413,987
+1,465% +$12.4M
ERAS icon
17
Erasca
ERAS
$6.31B
$10.1M 2.06%
7,367,996
-175,905
-2% -$302K
WVE icon
18
Wave Life Sciences
WVE
$993M
$8.49M 1.74%
1,050,374
+441,477
+73% +$4.83M
NBIX icon
19
Neurocrine Biosciences
NBIX
$15.7B
$8.03M 1.64%
+72,583
New +$9.19M
TVTX icon
20
Travere Therapeutics
TVTX
$6.19B
$7.33M 1.5%
408,849
+131,484
+47% +$2.67M
AKRO
21
CALL
DELISTED
Akero Therapeutics
AKRO
$7.31M 1.5%
180,600
-39,400
-18% -$1.67M
GOSS icon
22
Gossamer Bio
GOSS
$83.2M
$6.95M 1.42%
6,320,684
+148,837
+2% +$172K
GILD icon
23
Gilead Sciences
GILD
$181B
$6.95M 1.42%
62,029
+52,029
+520% +$5.37M
BBOT
24
BridgeBio Oncology
BBOT
$701M
$6.93M 1.42%
613,393
+100,024
+19% +$1.08M
ELUT icon
25
Elutia
ELUT
$39M
$6.76M 1.38%
2,670,056
+887,785
+50% +$2.68M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Silverarc Capital Management held 85 positions worth $489M, up 7% from $457M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Silverarc Capital Management deployed $69.7M of net new capital in Q1 2025, opening 24 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 72,583 shares worth $8.03M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Centessa Pharmaceuticals, an estimated $5.99M trimmed.

  • Silverarc Capital Management's largest Q1 2025 buy was Neurocrine Biosciences: 72,583 shares worth $8.03M.
  • Silverarc Capital Management added most to 89bio in Q1 2025, an estimated $12.4M increase.
  • Silverarc Capital Management's biggest Q1 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $5.99M.
  • Silverarc Capital Management fully exited Pliant Therapeutics in Q1 2025, selling an estimated $17.3M.
  • Silverarc Capital Management's ten largest holdings make up 49% of its $489M portfolio in Q1 2025.
  • Silverarc Capital Management opened 24 new positions and closed 16 in Q1 2025.
  • Silverarc Capital Management's portfolio value rose 7% quarter-over-quarter to $489M.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.